← All trials
NCT03903796
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 16, 2018
- Primary completion
- May 31, 2020
- Completion date
- May 31, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 963
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Lead sponsor
- Jilin UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.